SXI's Record FY26 Results Are Making Investors Choose: Real Growth Story or Another Anchored Premium?

Record FY26 results sharpened the valuation debate

Standex ended FY26 with a record adjusted EPS of $8.74 and 5.5% organic sales growth. The result did not turn the stock into an obvious growth-name crowd puller; instead, it sharpened a cleaner question: is Standex still best viewed as a steady industrial compounder, or does the recent run of execution justify a more growth-like multiple?

Why investors are split

Bulls point to a mix of results that looks stronger than the market's usual "stable industrial" label implies: - a full-year record adjusted EPS of $8.74 - 5.5% organic sales growth in FY26 - a Q4 book-to-bill of 1.18 overall, with Electronics at 1.27

Bears make a different point: steady execution does not automatically deserve growth-multiple treatment. That is the real fault line. The market may still be anchoring to SXI's industrial history while giving too little weight to recent improvements in growth, mix, and profitability.

One important boundary condition: if demand softens from the current book-to-bill level, the case for a meaningful re-rating weakens quickly.

The growth mix is improving, not just the headline rate

What changed after the release is less the headline growth rate than the sources of that growth. In Q4, Electronics organic growth reached 12.9%, new-product sales grew 43%, and sales into fast-growth markets contributed 31% of total sales. That matters because revenue tied to new designs and faster markets can be more durable than revenue driven by a simple cyclical pickup.

The pattern appears across multiple quarters

This does not look like a one-quarter burst. In Q2 FY26, Electronics increased 11.1% organically, new-product sales grew ~13%, and sales into fast-growth markets contributed ~28% of total sales. By year-end, the mix had moved higher again, consistent with Standex's claim that fast-growth-market sales reached approximately $264 million for fiscal 2026. That is the key shift: demand is becoming more weighted toward faster end markets and newer products, not just a broad industrial rebound.

Why the market still hesitates

Investors still hesitate because industrial false dawns are common, and "fast-growth markets" can sound stronger than the valuation should support. But the forward outlook matters. Management is now guiding to high single-digit to low double-digit organic growth in FY27, plans to launch more than 20 new products, and expects fast-growth-market sales to grow about 20%.

What would strengthen the re-rating case

The next checkpoints are straightforward: - sustained order strength around or above current book-to-bill levels - continued weight from new products and fast-growth markets - FY27 results that show the higher-growth mix is translating into durable revenue and margin performance